These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10072800)

  • 1. [Clinical and pathological analysis of liver injury resulting from rifampin and isoniazid].
    Xing T; Chen J; Zhang G
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Feb; 20(1):33-5. PubMed ID: 10072800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Liver damage from tuberculosis treatment].
    Keiner F
    Med Klin; 1981 Jun; 76(13):376-7. PubMed ID: 7254121
    [No Abstract]   [Full Text] [Related]  

  • 3. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The impact of antituberculosis drugs upon liver function in patients with positive HBVM].
    Chen GQ
    Zhonghua Jie He He Hu Xi Za Zhi; 1989 Apr; 12(2):89-90, 126. PubMed ID: 2791129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study on the cases in which INH or RFP was discontinued during treatment for pulmonary tuberculosis].
    Harada S; Takamoto M; Ishibashi T; Mohri M; Sato K; Yamagishi F; Sasaki Y; Tanabe K; Sato R; Fujino T; Tano M; Tanizawa M; Sakatani M; Morimoto T; Kawahara S; Hotta N; Shigeto E; Nishimura K; Abe T; Iwanaga T; Oe T; Shimazu K; Ebihara M; Nakagawa S; Kuba M;
    Kekkaku; 2001 May; 76(5):427-36. PubMed ID: 11449698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
    Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
    O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
    Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid hepatotoxicity after orthotopic liver transplantation.
    Schluger LK; Sheiner PA; Jonas M; Guarrera JV; Fiel IM; Meyers B; Berk PD
    Mt Sinai J Med; 1996; 63(5-6):364-9. PubMed ID: 8898542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombocytopenia following a re-introduction of rifampicin in a daily treatment. Apropos of a case].
    Beji M; Louzir B; Ben Rhomdane N; Zouari M; Mtimet B; Daghfous J
    Tunis Med; 1995 May; 73(5):201-3. PubMed ID: 9507284
    [No Abstract]   [Full Text] [Related]  

  • 13. An unusual recurrence of antitubercular drug induced hepatotoxicity in a child.
    Bhatia S; Tullu MS; Kannan S; Gogtay NJ; Thatte UM; Lahiri KR
    J Postgrad Med; 2011; 57(2):147-52. PubMed ID: 21654145
    [No Abstract]   [Full Text] [Related]  

  • 14. [Drug-induced hepatitis during a treatment associating isoniazid and rifampicin].
    Jean R; Bonnet H; Pages P; Dumas R; Greze J
    Ann Pediatr (Paris); 1972 Apr; 19(4):307-11. PubMed ID: 5075678
    [No Abstract]   [Full Text] [Related]  

  • 15. [Four cases of similar Hexheimer's reaction during the initial chemotherapy for tuberculosis bacillus].
    Lu H; Wu H; Liang G
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Dec; 18(6):348-50, 382-3. PubMed ID: 8762493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isoniazid-induced hepatic failure. Report of a case].
    Pereira RM; Tresoldi AT; Hessel G
    Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toxicity in the current treatment of pulmonary tuberculosis in children].
    Altet Gómez MN; Alcáide Megías J; Boque Genovard MA
    An Esp Pediatr; 1984 Jan; 20(1):18-27. PubMed ID: 6230974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Icterus caused by rifampicin and isoniazide].
    Haber I; Hubens H; Buyssens N
    Tijdschr Gastroenterol; 1974; 17(3):165-76. PubMed ID: 4454055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.